Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 4/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.50 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.50 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.50 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753170 | 0.88 | CACNA1F (0.48) | CACNA1FCACNA1DCACNA1SCACNA1CTARBP2 | |
| SCHEMBL1244895 | 0.86 | PTGS2 (0.46) | MAPTCA9CA1CA2CA12 | |
| SCHEMBL13214659 | 0.79 | LMNA (0.43) | CACNA1FCACNA1DCACNA1SCACNA1CHTT | |
| SCHEMBL13674 | 0.75 | CACNA1F (0.62) | CACNA1FABCB1CACNA1DCACNA1SCACNA1C | |
| SCHEMBL18792559 | 0.74 | CACNA1F (0.48) | CACNA1FABCB1CACNA1DCACNA1SCACNA1C | |
| SCHEMBL3608887 | 0.74 | PTGS1 (0.53) | ABCB1HTTMAPTALDH1A1MAPK1 | |
| SCHEMBL104403 | 0.73 | ALDH1A1 (0.43) | HTTRAB9AMAPTMEN1NPC1 | |
| SCHEMBL3456699 | 0.73 | RAB9A (0.74) | CACNA1FABCB1CACNA1DCACNA1SCACNA1C | |
| SCHEMBL14710878 | 0.72 | HTT (0.50) | CACNA1FABCB1CACNA1DCACNA1SCACNA1C | |
| SCHEMBL14709097 | 0.72 | HTT (0.57) | CACNA1FABCB1CACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2011013729-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | オンコセラピー・サイエンス株式会社 (JP) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | CACNA1F 2523/4885ABCB1 1348/4885CACNA1D 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.